Furthermore, the observation that ERα-mediated transient up-regulation of HER2 leads to endocrine resistance suggests that therapeutic regimens leading to dual blockade of ERα and HER2 even in ER+ breast cancers without HER2 amplification or primarily HER2 overexpression might be therapeutically relevant. Here, ERBB2 is linked to breast carcinoma.